Biosimilars in India: Opportunity or Confusion?

General
1

Biosimilars are “similar” versions of complex biologic medicines such as insulin, monoclonal antibodies, and growth factors designed to match already approved biologics without clinically meaningful differences. In India, they represent both a major public health opportunity and a source of ongoing confusion.

The Opportunity

  • Lower treatment costs for chronic and life-threatening diseases like cancer, autoimmune disorders, and diabetes

  • Improved access in a system where out-of-pocket healthcare spending remains high

  • Leverages India’s strong generic manufacturing base to expand into high-value biologics

  • Boosts domestic biotech innovation and global export potential

  • Supports long-term goals of affordable, scalable healthcare

The Confusion

  • Biologics are structurally complex and produced in living cells, making exact replication impossible

  • Minor manufacturing variations may affect safety or efficacy

  • Regulatory pathways are more complex than for small-molecule generics

  • Limited clarity around interchangeability and automatic substitution

  • Gaps in pharmacovigilance awareness and physician confidence

What do you think? Will the Biopharma SHAKTI initiative help India’s pharmaceutical industry retain its position as a global manufacturer of biosimilars?

MBH/PS

1 Like
2

Biosimilars may help reduce the drug manufacturing cost significantly. However, regulating the drugs and long-term monitoring of outcomes is of utmost importance.

1 Like